- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway ; day:2 ; month:2 ; year:2018 ; pages:1-11
PharmacoEconomics ; (2.2.2018), 1-11
- Urheber
-
Wisløff, Torbjørn
- Beteiligte Personen und Organisationen
-
White, Richard
Dalgard, Olav
Amundsen, Ellen J.
Meijerink, Hinta
Løvlie, Astrid Louise
Kløvstad, Hilde
SpringerLink (Online service)
- DOI
-
10.1007/s40273-017-0604-3
- URN
-
urn:nbn:de:1111-201803302447
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wisløff, Torbjørn
- White, Richard
- Dalgard, Olav
- Amundsen, Ellen J.
- Meijerink, Hinta
- Løvlie, Astrid Louise
- Kløvstad, Hilde
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study